文献速递慢性肾脏病血液净化与透析肾血管病与高血压

Sotatercept对血红蛋白、骨骼及血管钙化的安全性及效应

Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification.
PubMed 文献 · Kidney Int Rep · 2019-08-13

两项II期随机多中心研究评估sotatercept在终末期肾病患者中的安全性及对血红蛋白、骨密度和腹主动脉钙化的影响。

要点

  • sotatercept在ESKD患者中安全性良好,常见不良事件为高血压、肌肉痉挛、头痛等。
  • 血红蛋白达标率呈剂量相关趋势,但REN-002结果与REN-001不完全一致。
  • 股骨颈皮质骨密度增加和腹主动脉钙化减缓呈剂量相关趋势,安慰剂组无此现象。

核心结论

  • sotatercept在ESKD患者中表现出良好的安全性,并与血管钙化减缓的剂量相关趋势相关。
  • 血红蛋白浓度和骨密度的改善趋势不太一致。

研究设计与样本

  • REN-001和REN-002为II期、多中心、随机研究。
  • REN-002纳入50例患者,接受sotatercept 0.1‒0.4 mg/kg静脉或0.13‒0.5 mg/kg皮下注射99天。

主要发现

  • REN-001中达到目标血红蛋白反应(>10 g/dl [6.21 mmol/l])的频率呈剂量相关且高于安慰剂:0.3 mg/kg组33.3%,0.5 mg/kg组62.5%,0.7 mg/kg组77.8%,0.7 mg/kg(第1、2次)/0.4 mg/kg(第3‒15次)组33.3%,安慰剂组27.3%。
  • REN-002血红蛋白结果类似:静脉组16.7%-57.1%,皮下组11.1%‒42.9%。
  • 仅REN-001中接受sotatercept的患者出现股骨颈皮质骨密度增加≥2%的剂量相关达标率(0.3‒0.7 mg/kg组20.0%‒57.1%,安慰剂组0.0%)。
  • REN-001中sotatercept组较安慰剂组更多患者实现Agatston评分增加≤15%(60%‒100% vs. 16.7%),腹主动脉钙化呈剂量相关减缓。
  • 治疗期间最常见不良事件为高血压、肌肉痉挛、头痛、动静脉瘘部位并发症和流感,治疗组和安慰剂组均可见。

临床怎么用

  • sotatercept可能作为ESKD患者改善贫血、骨密度和血管钙化的潜在治疗选择,但需进一步研究验证。
  • 临床使用中应监测血压、肌肉痉挛等不良事件。

局限性

  • 血红蛋白和骨密度改善趋势不一致,需更大规模研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with end-stage kidney disease (ESKD) exhibit anemia, chronic kidney disease‒mineral bone disorder (CKD-MBD), and cardiovascular disease. The REN-001 and REN-002 phase II, multicenter, randomized studies examined safety, tolerability, and effects of sotatercept, an ActRIIA-IgG1 fusion protein trap, on hemoglobin concentration; REN-001 also explored effects on bone mineral density (BMD) and abdominal aortic vascular calcification. METHODS: Forty-three patients were treated in REN-001 (dose range: sotatercept 0.3‒0.7 mg/kg or placebo subcutaneously [s.c.] for 200 days) and 50 in REN-002 (dose range: 0.1‒0.4 mg/kg i.v. and 0.13‒0.5 mg/kg s.c. for 99 days). RESULTS: In REN-001, frequency of achieving target hemoglobin response (>10 g/dl [6.21 mmol/l]) with sotatercept was dose-related and greater than placebo (0.3 mg/kg: 33.3%; 0.5 mg/kg: 62.5%; 0.7 mg/kg: 77.8%; 0.7 mg/kg [doses 1 and 2]/0.4 mg/kg [doses 3‒15]: 33.3%; placebo: 27.3%). REN-002 hemoglobin findings were similar (i.v.: 16.7%-57.1%; s.c.: 11.1%‒42.9%). Dose-related achievement of ≥2% increase in femoral neck cortical BMD was seen among only REN-001 patients receiving sotatercept (0.3‒0.7 mg/kg: 20.0%‒57.1%; placebo: 0.0%). Abdominal aortic vascular calcification was slowed in a dose-related manner, with a ≤15% increase in Agatston score achieved by more REN-001 sotatercept versus placebo patients (60%‒100% vs. 16.7%). The most common adverse events during treatment were hypertension, muscle spasm, headache, arteriovenous fistula site complication, and influenza observed in both treatment and placebo groups. CONCLUSION: In patients with ESKD, sotatercept exhibited a favorable safety profile and was associated with trends in dose-related slowing of vascular calcification. Less-consistent trends in improved hemoglobin concentration and BMD were observed.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Coyne DW, Singh HN, Smith WT, et al. Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. Kidney Int Rep. 2019. PMID: 31891000. doi:10.1016/j.ekir.2019.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。